Hemodynamic and vascular responses to antihypertensive treatment with adrenergic blocking agents: A review by Sannerstedt, Rune & Conway, James
Review 
Hemodynamic and vascular responses to 
antihypertensive treatment with adrenergic 
blocking agents: A review 
Rune Sannerstedt, M.D. 
James Conway, M.D. 
Ann Arbor, Mich. 
P atients with established, uncompli- cated arterial hypertension are charac- 
terized by a normal resting cardiac output 
and an increased systemic vascular re- 
sistance affecting the renal vascular bed 
most prominently.l-3 The elevated blood 
pressure can, generally speaking, be low- 
ered by reducing the cardiac output, fower- 
ing the systemic vascular resistance, or 
through a combination of both. An ideal 
antihypertensive agent should lower the 
blood pressure by reducing both the sys- 
temic and particularly the renal vascular 
resistance both at rest and during stress 
situations of various kinds. 
As this field is reviewed it becomes ap- 
parent that the available information on 
antihypertensive drugs is based mainly on 
acute animal experiments and parenteral 
administration to human subjects. Our 
knowledge on possible changes induced by 
long-term treatment is poor. This discus- 
sion, therefore, considers three widely used 
hypotensive agents with adrenergic block- 
ing properties-Rauwolfia preparations, 
guanethidine, and methyldopa-and sepa- 
rately deals with: (1) acute effects, (2) ef- 
fects of short-term treatment (less than 4 
weeks), and (3) effects of long-term treat- 
ment. 
Rauwolfia preparations 
AC& e$ects. Only two studies of the 
acute effects on cardiac hemodynamics are 
available.4,5 In one of them, the effect of 
2.5 mg. of reserpine given intramuscularly 
was observed 4 hours after administration.4 
The blood pressure dropped in all cases. In 
patients with borderline hypertension and 
elevated cardiac output, the cardiac output 
decreased, while in those with normal car- 
diac output but elevated systemic vascular 
resistance, the latter decreased. The heart 
rate did not change. During head-up tilting, 
five of eleven reserpine-treated patients 
fainted, indicating an orthostatic action 
which is not generally seen with this agent. 
In the other study on only four subjects, 
both cardiac output and systemic resistance 
fell after intravenous administration of 1.0 
to 5.0 mg.5 
After intravenous administration of reser- 
pine, a slight reduction in glomerular filtra- 
tion rate was noted, and the excretion of 
water and electrolytes decreased.6 
Parenteral reserpine increased digital 
blood flow significantly in both normoten- 
sive and hypertensive subjects.’ The mean 
blood pressure and systemic resistance fell 
without consistent changes in heart 
rate. 
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The overshoot of blood pressure follow- 
ing the Valsalva maneuver is not apparently 
inhibited by reserpine given parenterally 
in moderate doses,8 but the pressor response 
to infused norepinephrine may be slightly 
increased.4 
Efects of short-term treatment. Syrosingo- 
pine, in a dosage of 1.5 to 6.0 mg. given 
intramuscularly daily for seven days to 
normal volunteers, resulted in a lower blood 
pressure, but there were no definite changes 
in heart rate or cardiac output.g It did not 
interfere with the response to recumbent 
exercise. 
In hypertensive patients studied for one 
week before and after oral syrosingopine, it 
was noted that although the resting arterial 
pressure was almost brought to normal, 
there was still a considerable pressure rise 
during sitting exercise.*O Similarly, the 
pressor responses to noxious stimuli, such 
as the cold pressor test, were una1tered.n 
In hypertensive patients, oral reserpine 
in large doses resulted in a marked reduc- 
tion in systemic resistance and even an in- 
creased cardiac output after one week of 
treatment, while renal blood flow decreased 
and renal resistance increased.‘2 
Efects of long-term treatment. In the study 
mentioned above, the systemic resistance 
continued to be reduced after 6 weeks of 
treatment, but the renal blood flow had re- 
turned to about control levelsi Likewise, 
the renal hemodynamics in hypertensive 
patients treated for three months with oral 
reserpine, 3.0 to 6.0 mg. daily, did not 
show consistent changes.6 
After three months of treatment with 
oral reserpine, a dosage of 0.75 mg. daily, 
a fall in both resting and exercising blood 
pressure levels was reported to occur in 
hypertensive patients.i3 The decrease was 
felt to be due to a lowered resistance, as 
there were no changes in the resting cardiac 
output or the output response to exercise. 
Reserpine was shown to block both arte- 
rial and venous reflex vasoconstriction in 
normal subjects after oral treatment for 
up to four months.‘4 
The weight gain seen during treatment 
with Rauwolfia drugs is probably not due 
to Auid retention in most of the cases, as 
the extracellular fluid volume was shown 
to maintain a constant ratio to total body 
weight after reserpine given orally from 
four weeks to four months.15 This is sup- 
ported by studies on the body fluid com- 
partments before and after parenteral ad- 
ministration of reserpine for six days.i6 
Conclusion. Most authors report a favor- 
able pattern of response to oral reserpine 
with lowered systemic vascular resistance 
as the main feature, without reduction in 
the renal blood flow. There is conflicting 
evidence concerning the effect of reserpine 
on the hemodynamic responses to stressful 
procedures. 
The weight gain seen during treatment 
with Rauwolfia preparations is probably 
not due to fluid retention. It should also be 
noted that most of the data for reserpine 
were obtained for dosage levels which are 
not recommended for continued therapy. 
Guanethidine 
Acute efects. The acute effects of paren- 
terally administered guanethidine, usually 
in doses of 10 to 25 mg. intravenously, have 
been studied by several authors.17-23 Within 
10 minutes after an intravenous injection, 
there is usually a short-lived pressor phase 
with increased systolic and diastolic pres- 
sures in both normotensive and hyperten- 
sive subjects.“O The depressor phase which 
follows is characterized by a substantial 
reduction in cardiac output. The systemic 
resistance is not altered.23 The effect on the 
heart rate is variable.20 In patients with 
pulmonary hypertension, there is a reduc- 
tion in pulmonary pressure without change 
in pulmonary resistance.‘* In normal sub- 
jects and in patients with arterial hyper- 
tension, a small reduction in pulmonary 
vascular resistance has been described.rg 
After taking guanethidine intravenously, 
the response to supine exercise has been 
reported to be largely unchanged in both 
normotensive and hypertensive subjects,rg 
but the increase in heart rate was smaller. 
The blood pressure increased in the same 
manner as in the control study. 
The reduction in cardiac output at rest 
in recumbency is accompanied by a de- 
crease in renal blood flow and glomerular 
filtration rate. In both normotensive and 
hypertensive subjects, the water and so- 
dium excretion diminish.22~24 The cerebral 
and hepatoportal blood flows have been re- 
ported to fa11.17~20 If the patient is tilted, a 
further decrease of both the blood pressure 
and cardiac output is obtained, and sys- 
temic resistance falls.?? 
The blood pressure overshoot follow- 
ing the Valsalva maneuver is completely 
blocked by guanethidine, and other vaso- 
constrictor reflexes are markedly inhibi- 
ted.1gJ0s”5 The response to tyramine and 
ephedrine infusions is not significantly al- 
tered, but the pressor effect of single doses 
of norepinephrine is enhanced.20rz5 
Efects of short-term treatment. After 4 to 
10 days of oral guanethidine, the cardiac 
output in hypertensive patients was lower 
in the recumbent position, and the decrease 
became more marked after tilting, while the 
systemic resistance was only moderately 
lowered.“6 The heart rate decreased and an 
impaired pressor response to noxious stim- 
uli, such as the cold pressor test, was re- 
ported.“’ 
Both the renal plasma flow and glomeru- 
lar filtration rate were found to decrease in 
hypertensive subjects, but the vascular re- 
sistance was unchanged.26 These changes 
became more marked after tilting. In nor- 
mal subjects, on the other hand, an in- 
creased renal blood flow and a decreased 
resistance after taking oral guanethidine 
in a dosage of 10 mg. daily for 5 to 7 days 
have been described.“” 
The digital vascular reactivity to norep- 
inephrine increased after oral guanethi- 
dine given to hypertensive patients, but the 
drug did not produce vasodilatation in 
the digit with the subjects in the resting 
recumbent position. 28 In normal subjects 
the drug was shown to block both arterial 
and venous vasoconstriction.‘” 
Efects of long-term treatment. After sta- 
bilization of the blood pressure on treat- 
ment of 12 patients with oral guanethidine, 
neither supine nor standing cardiac output 
was significantly changed, and the systemic 
vascular resistance was lower.22Jg The heart 
rate had decreased. On walking, the sys- 
temic pressures of the hypertensive subjects 
were lower than before treatment with no 
significant change in cardiac output.2g 
Others observed a fall in blood pressure, 
instead of the usual increase, during exer- 
cise with guanethidine.sO 
Guanethidine in large oral doses to nor- 
mal subjects for four weeks resulted in a 
lower resting heart rate, but there were no 
significant changes in mean arterial pres- 
sure or cardiac index.’ d1 During supine exer- 
cise, the cardiac index and mean pressure 
were lower than in the control study. 
After 8 to 30 days of oral guanethidine, 
in patients with severe hypertension the 
renal plasma flow and glomerular filtration 
rate were found to be decreased in both the 
lying and standing positions, as were the 
excretion of sodium, potassium, and water.32 
The blood volume has been reported to 
be significantly increased in hypertensive 
patients after oral guanethidine for 7 to 21 
days.33 Similar results were found after one 
year of treatment. 3J Total exchangeable 
sodium increased, and creatinine clearance 
fell. In normal subjects, on the other hand, 
oral guanethidine for 7 to 21 days was 
found to increase the plasma volume with- 
out any sodium retention.35 
Conclusion. There are a fairly large num- 
ber of reports on the acute and subacute 
effects in man of guanethidine, but long- 
term studies are few. 
The hemodynamic responses to guanethi- 
dine are similar to those with ganglionic 
blocking agents. The main immediate effect 
is probably on the cardiac output, leaving 
the systemic vascular resistance little 
changed; but the long-term studies indi- 
cate that cardiac output may return to 
normal. Hypotension during exercise can 
occur. 
Impairment of the renal blood flow is to 
be anticipated during treatment with 
guanethidine. The weight gain seen is due 
to increased plasma volume, probably 
secondary to sodium retention. 
Methyldopa 
Acute effects. The decrease in recumbent 
blood pressure, seen after parenteral admin- 
istration of methyldopa to hypertensive 
patients, is ascribed by some authors to a 
lower systemic vascular resistance with 
only minor changes in the cardiac out- 
put.23,26 Renal vascular resistance is reduced 
substantially, and therefore the renal blood 
flow and glomerular filtration rate are left 
uncompromised despite the blood pressure 
reduction. 
It has been reported that the same pat- 
tern of systemic and renal hemodynamic 
changes is maintained while in the erect 
position, and the increase in systemic and 
renal resistance seen after tilting in the 
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control state is abolished after methyl- 
dopa. 
Different results have, however, been re- 
ported by others, who have found the blood 
pressure reduction to be due to a decreased 
output with an unchanged systemic vascu- 
lar resistance.37s38 The heart rate fell sig- 
nificantly in one study,37 but not in another 
where it even increased when methyldopa 
was given to a series of labile hyperten- 
sives.38 Also in that series, the recumbent 
blood pressure reduction was due to a de- 
creased cardiac output. However, the 
greater reduction in mean blood pressure 
with 60 degree head-up tilting occurred 
without a further reduction in cardiac out- 
put, and the systemic resistance was 
lowered in this position. This was thought 
to be due to orthostatic loss of reflex arte- 
riolar constriction. 
Methyldopa given intravenously has not 
been shown to produce consistent effects 
on the hypertensive overshoot seen after 
the Valsalva maneuver.37 
Effects of short-term treatment. After tak- 
ing oral methyldopa for 7 to 16 days, the 
blood pressure in hypertensive patients fell 
without change in cardiac output, indi- 
cating a lowered systemic resistance.3g The 
heart rate was unchanged. Tilting feet 
downward did not produce an exag- 
gerated fall in blood pressure or cardiac 
output when compared with the control 
study.40 
During upright exercise, the blood pres- 
sure level was reported to be markedly 
lower than before treatment, but without 
tendency to exercise hypotension.3g~41~42 The 
pressor response to noxious stimuli, such as 
the cold pressor test, was described to be 
impaired in hypertensive patients on oral 
methyldopa,27 and the response to the Val- 
salva maneuver was completely abolished 
in eight of ten patients after oral treatment 
with methyldopa.3g 
Oral methyldopa taken for 6 to 19 days 
on the whole did not produce consistent 
changes in glomerular filtration rate.39 Pa- 
tients responding to methyldopa with a 
blood pressure decrease showed an in- 
creased renal blood flow with lower calcu- 
lated renal vascular resistance. These re- 
sults have been confirmed for hypertensive 
patients with reduced renal function.43 
The pressor response to norepinephrine 
was only slightly increased, but strikingly 
prolonged, after treatment with methyl- 
dopa.4D After tyramine, on the other hand, 
the pressor effect was markedly enhanced. 
An increased digital vascular reactivity 
to norepinephrine has also been demon- 
strated.28 The drug produces significant 
digital vasodilatation in the recumbent 
hypertensive patient,28 and blocks both 
arterial and venous reflex vasoconstriction 
in normal subjects.14 
When administered as therapy for hyper- 
tensive patients, methyldopa has been 
shown to have a smaller orthostatic effect 
than guanethidine for a given change in 
recumbent blood pressure.23s44 
Effects of long-term treatment. After sta- 
bilization of therapy on oral methyldopa, 
the systemic resistance was lower in both 
the supine and standing positions in eight 
of ten hypertensive patients studied.2g The 
heart rate was also reduced. On walking, 
the blood pressure level was lower than 
before treatment. The exercise cardiac out- 
put was, nevertheless, more than 20 per 
cent higher than in the control study, re- 
sulting in markedly lower resistance levels 
during exercise. 
Conclusion. Though opinions differ, it 
seems that methyldopa acts primarily to 
reduce systemic resistance with no appre- 
ciable effect on cardiac output. 
Hypotension during exercise does not 
occur. The renal blood flow appears to be 
maintained. However, little information is 
available on the long-term effect. 
Summary 
While the pharmacological effects of the 
three agents discussed (reserpine deriva- 
tives, guanethidine, and methyldopa) ap- 
pear to depend upon interference with sym- 
pathetic nervous activity, they differ in 
their effects in man. 
After acute administration, there is a fall 
in blood pressure with each agent, but with 
reserpine and methyldopa, cardiac output 
is little affected. With methyldopa, the 
renal resistance appears to fall. Guanethi- 
dine produces a sharp fall in the cardiac 
output and renal blood flow. 
After treatment for a few days with 
these agents, the differences in their actions 
are less apparent, and from the very lim- 
ited information available on long-term 
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therapy, each of these agents achieves its 
hypotensive effect without reduction in 
cardiac output. The renal blood flow re- 
mains at control levels with reserpine and 
methyldopa but is still somewhat reduced 
with guanethidine. 
From the practical point of view, there- 
fore, the decision to use one or another of 
these agents should rest upon differences in 
their clinical effectiveness and side effects. 
There is an urgent need for information on 
the changes in the action of these drugs 
during long-term therapy. These changes 
could be caused by the drugs’ pharmacolog- 
ical effects or by physiological adaptations 
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